Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356825 | 0.90 | HTR1A (0.53) | HTR1AKCNH2HTR6SLC6A4HTR7 | |
| SCHEMBL6361481 | 0.87 | HTR1A (0.41) | HTR1AKCNH2HTR6SLC6A4HTR7 | |
| SCHEMBL6354737 | 0.87 | HTR1A (0.66) | HTR1AKCNH2HTR6SLC6A4HTR7 | |
| SCHEMBL6358396 | 0.85 | HTR1A (0.46) | HTR1AKCNH2SLC6A4HTR7DRD2 | |
| SCHEMBL6361478 | 0.85 | HTR1A (0.49) | HTR1AKCNH2HTR6SLC6A4HTR7 | |
| SCHEMBL6356505 | 0.85 | HTR6 (0.39) | HTR1AKCNH2HTR6SLC6A4HTR7 | |
| SCHEMBL6356692 | 0.84 | HTR1A (0.38) | HTR1AKCNH2SLC6A4HTR7MAPT | |
| SCHEMBL8978839 | 0.84 | HTR1A (0.37) | HTR1AKCNH2SLC6A4HTR7 | |
| SCHEMBL8978746 | 0.84 | HTR1A (0.39) | HTR1AKCNH2SLC6A4HTR7 | |
| Hydrochloric Acid SCHEMBL8786692 | 0.83 | HRH4 (0.42) | HTR1AHTR7LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0464604-B1 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-03-29 | — | — | EP | claimed |
| EP-0464604-A2 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | claimed |
| US-5077293-A | Antidepressants | BRISTOL-MYERS SQUIBB CO. (US) | 1991-12-31 | — | — | US | claimed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | HTR1A 22/4885KCNH2 3678/4885HTR6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.